Serum Levels of Soluble IL-6 Receptor in Multiple Myeloma as Indicator of Disease Activity

Acta Haematologica

Volumn 97, Issue 4, 1997, Pages 191-195

  Papadaki, Helen ^a   Kyriakou, Despina ^a   Foudoulakis, Andreas ^a   Markidou, Fotini ^a   Alexandrakis, Michael ^a   Eliopoulos, George D ^a  

^a UNIVERSITY OF CRETE   (Greece)

Author keywords

Multiple myeloma; Plasma cell leukaemia; Soluble IL 6 receptor

Indexed keywords

BETA 2 MICROGLOBULIN; FERRITIN; HEMOGLOBIN; INTERLEUKIN 6 RECEPTOR; SERUM ALBUMIN;

ARTICLE; BLOOD LEVEL; BONE LESION; CELL GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME IMMUNOASSAY; FERRITIN BLOOD LEVEL; HUMAN; HUMAN CELL; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MYELOMA CELL; PLASMA CELL DYSCRASIA; PLASMACYTOMA; PRIORITY JOURNAL;

ANTIGENS, CD; BETA 2-MICROGLOBULIN; BONE MARROW; FERRITINS; HUMANS; IMMUNOENZYME TECHNIQUES; L-LACTATE DEHYDROGENASE; LEUKEMIA, MYELOID, CHRONIC; MULTIPLE MYELOMA; NEOPLASM PROTEINS; NEOPLASMS, MULTIPLE PRIMARY; OSTEOLYSIS; PARAPROTEINEMIAS; PLASMACYTOMA; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-6; SEVERITY OF ILLNESS INDEX; TUMOR MARKERS, BIOLOGICAL;

EID: 0030959906     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000203682     Document Type: Article

References (25)

1. Kawano M, Hirano T, Matsuda T, Taga T. Horii Y. Iwato W. Asaoku H. Tang B, Tanabe O, Tanaka H. Kuramoto A. Kishimoto T: Autocrine generation and essential requirement of BSF-2/IL-6 for human multiple myeloma. Nature 1988:332:83-85.
2. Klein B. Zhang X-G. Jourdan M, Content J, Houssiau E, Aarden L. Piechaczyk M, Bataillc R: Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interieukin-6. Blood 1989;73:517-526.
3. Taga T, Hibi M, Hirata Y. Yamassaki K. Yasu-kawa K. Matsuda T. Hirano T, Kishimoto T: !nterleukin-6 triggers the association of its receptor with a possible signal transducer, gp 130. Cell 1989;58:573-581.
4. Hibi M, Murakami M, Saito M, Hirano T, Taga T, Kishimoto T: Molecular cloning and expression of an IL-6 signal transducer, gpl 30. Cell 1990;63:1149-1157.
5. Bazan JF: Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA 1990;87:6934-6938.
6. Hitzlcr JK, Martinez-Valdez H, Bergsagel DB, Minden MD, Messner HA: Role of intcrleukin-6 in the proliferation of human multiple myeloma cell lines OCI-My 1 to 7 established from patients with advanced stage of the disease. Blood 1991;78:1996-2004.
7. Novick D, Engelman H, Wallach D, Rubinstein M: Soluble cytokine receptors arc present in normal human urine. J Exp Med 1989:170: 1409-1414.
8. Honda M. Yamamoto S. Cheng M, Yasukawa K, Suzuki S, Saito T, Osugi Y. Tokunaga T, Kishimoto T: Human soluble IL-6 receptor: Its detection and enhanced release by HIV infection. J Immunol 1992;148:2175-1280.
9. Taga T. Hibi M. Murakami M, Saito M, Yawa-ta H. Narazaki M. Hirata Y, Sugita T, Yasukawa K. Hirano T, Kishimoto T: Interleukin-6 receptor and signals; in Kishimoto T (ed): Interleukins: Molecular Biology and Immunology. Basel, Kargcr. 1992, pp 181-204.
10. Yasukawa K. Saito T, Fukunaga T, Sekimori Y. Koishihara Y. Fukui H, Osugi Y, Matsuda T. Hirano T, Taga T, Kishimoto T: Purification and characterization of soluble human IL-6 receptor expressed in CHO cells. J Biochem 1990;108:673-676.
11. Gaillard JP, Bataille R. Brailly H, Zuber C, Yasukawa K, Attal M. Taga T, Kishimoto T, Klein B: Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur J Immunol 1993;23:820-824.
12. Kyrtsonis M-C, Dedoussis G, Zervas C, Peri-fanis V, Baxcvanis C, Stamatclou M, Maniatis A: Soluble interleukin-6 receptor (sIL-6R), a new prognostic factor in multiple myeloma. Br J Haematol, in press.
13. Hirano T: Interleukin 6 (IL-6) and its receptor: Their role in plasma cell neoplasias. Int J Cell Cloning 1991;9:166-184.
14. Zhang X-G, Klein B, Bataille R: Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood 1989;74:11-13.
15. Oken MM: Multiple myeloma. Med Clin North Am 1984;68:757-787.
16. Durie BGM: Staging and kinetics of multiple myeloma. Semin Oncol 1986;13:300-309.
17. Durie BGM. Salmon SE: A clinical staging system for multiple myeloma. Cancer 1975;36: 842-854.
18. Castell JV. Klapproth J, Gross V. Walter E, Andus T. Snyers L. Content J, Heinrich PC: Fate of intcrlcukin-6 in the rat. Involvement of skin in its catabolism. Eur J Biochem 1990; 189:113-118.
19. Durie BGM, Russell DH, Salmon SE: Reappraisal of plateau phase in myeloma. Lancet 1980;2:65-68.
20. Grcipp P, Kyle R: Clinical, morphological and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significance, and smouldering multiple myeloma. Blood 1983:62:166-171.
21. Boccadoro M. Gavarotti P, Fossati G, Pilcri A, Marmont F, Neretto G. Galamini A, Volta C, Tribalto M, Testa MG, Amadori S, Mandelli F. Durie BGM: Low plasma cell 'H-thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: A reliable indicator of patients not requiring therapy. Br J Haematol 1984,58:689-696.
22. Bataille R. Jourdan M. Zhang X-G. Klein B: Serum levels of interleukin-6, a potent myeloma-cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 1989;84:2008-2011.
23. Bataille R. Boccadoro M, Klein B, Durie B, Piler: A: C-reactive protein and T-microglobu-lin produce a simple and powerful myeloma staging system. Blood 1992:80:733-737.
24. Ludwig H. Nachbaur DM, Fritz E, Krainer M, Huber H: Intcrleukin-6 is a prognostic factor in mult:ple myeloma (letter). Blood 1991;77: 2794-2795.
25. Schwabe M, Brini AT, Bosco MC, Rubboli F, Egawa M. Zhao J. Princler GL. Kung HF: Disruption by interferon-alpha of an autocrine in-terleukin-6 growth loop in IL-6-depcndent U266 myeloma cells by homologous and heterologous downregulation of the IL-6 receptor alpha- and beta-chains. J Clin Invest 1994;94: 2317-2325.